Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-172P (RNA, U6 small nuclear 172, pseudogene) is a non-coding, genomically-encoded pseudogene corresponding to a defective or relic version of the U6 small nuclear RNA gene. Pseudogenes such as RNU6-172P do not encode functional snRNA and are not translated into proteins, nor do they act as biochemical receptors, enzymes, or signaling molecules[6][7]. The original U6 small nuclear RNA (snRNA) is an essential non-coding RNA involved in the splicing of pre-mRNA in the spliceosome[1][3][5]; however, RNU6-172P lacks the proper sequence or regulatory elements for expression and functional activity in splicing. Sequence analyses have revealed that U6 snRNA pseudogenes often bear sequence similarity to authentic U6 RNAs but contain deletions, duplications, or mutations that render them inactive[7]. The pseudogene status means this locus is generally biologically silent and unlikely to have direct clinical or therapeutic relevance. There are no known drugs, clinical biomarkers, or disease implications specifically associated with RNU6-172P[6]. Any significance is limited to potential roles as genomic evolutionary markers or rare regulatory sequences, but this is not established for RNU6-172P. Notes on correctness: If referenced as a receptor, enzyme, transporter, or other druggable target, this is incorrect; RNU6-172P is a pseudogene lacking any known therapeutic or biological activity. It should be distinguished from genuine U6 snRNA gene loci (such as RNU6-1)[2][3], which encode the functional RNA used in nuclear splicing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 172, pseudogene (RNU6-172P).